ETFMG Treatments, Testing and Advancements ETF (GERM): Price and Financial Metrics ETF
GERM Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
| Current price | $16.68 | 52-week high | $21.70 |
| Prev. close | $16.90 | 52-week low | $15.67 |
| Day low | $16.68 | Volume | 1,000 |
| Day high | $16.78 | Avg. volume | 2,115 |
| 50-day MA | $17.91 | Dividend yield | 1.25% |
| 200-day MA | $18.37 |
GERM Stock Price Chart Interactive Chart >
ETFMG Treatments, Testing and Advancements ETF (GERM) ETF Bio
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index. The fund invests at least 80% of its total assets in the component securities of the index. The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified.
GERM ETF Info
| Issuer | ETF Managers Group |
| Expense Ratio | 0.68% |
| Underlying Index | Prime Treatments, Testing and Advancements Index |
| Asset Class | Equity |
| Sector | Health & Biotech ETFs |
| Assets Under Management (AUM) | 9.34M |
| Net Asset Value (NAV) | $16.99 |
| Options? | Yes |
| Total Holdings | 1 |
GERM Top Holdings
| Symbol | Company | % of Total |
| GERM | ETFMG Treatments Testing and Adv ETF | 0% |
GERM Price Returns
| 1-mo | -7.48% |
| 3-mo | -10.02% |
| 6-mo | 6.44% |
| 1-year | -18.19% |
| 3-year | -55.61% |
| 5-year | N/A |
| YTD | -14.46% |
| 2023 | -11.56% |
| 2022 | -36.78% |
| 2021 | 14.86% |
| 2020 | N/A |
| 2019 | N/A |
GERM Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||